Sinocelltech Group Ltd (688520.SS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE100003ZL3
Sinocelltech Group Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 2.51 bn CNY | 1.56 bn CNY |
| Gross profit | 2.39 bn CNY | 1.56 bn CNY |
| Operating income | 568.41 m CNY | -427.35 m CNY |
| EBIT | 217.51 m CNY | -554.62 m CNY |
| Net income | 111.95 m CNY | -553.29 m CNY |
| Diluted EPS – continuing operations | 0.24 CNY | -1.29 CNY |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Sinocelltech Group Ltd
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, viral infections, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell non-Hodgkin's lymphoma; Anjiarun, an adalimumab biosimilar for the treatment of various autoimmune diseases; Anbezu, a bevacizumab biosimilar for the treatment of various solid tumors; SCTV01, a series of recombinant protein vaccines for multiple variants of the new coronavirus; Fenolimab, a recombinant humanized anti-PD-1 monoclonal antibody for the treatment of solid tumors; and SCT1000, a recombinant 14-valent human papillomavirus (HPV) virus-like particle vaccine for the prevention of various cancers. It also develops other clinical-stage products, including SCT650C for the treatment of plaque psoriasis, axial spondylarthritis, and other autoimmune diseases; SCTC21C for the treatment of CD38-positive blood cancers; SCTB35 for the treatment of diseases, such as CD20-positive B-cell non-Hodgkin's lymphoma; SCTB14 for immunotherapy of multiple solid tumors; SCTB41 for multiple solid tumor immunotherapy; SCTV02 to prevent respiratory diseases; SCTV04C to prevent herpes zoster; SCT520FF, an anti-angiogenic biopharmaceutical product; and SCTT11 for the treatment of thyroid eye disease. The company was founded in 2007 and is based in Beijing, China. Sinocelltech Group Limited operates as a subsidiary of Lhasa Aili Investment Consulting Co., Ltd.
More stocks
- Sendas Distribuidora S.A. (ASAI3.SA)
- Gambol Pet Group Co Ltd Class A (301498.SZ)
- Ashmore Group PLC (ASHM.L)
- Savills PLC (SVS.L)
- Paragon Banking Group PLC (PAG.L)
- WG Tech JiangXi Co Ltd (603773.SS)
- Vestis Corp (VSTS)
- KAISER ALUMINUM CORP (KALU)
- Fabege AB (FABG.ST)
- Chemours Co (CC)
- Gimv NV (GIMB.BR)
- Xinhuanet Co Ltd (603888.SS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.